Dr. Alexandra Goll holds vast managerial and operational experience in the international pharmaceutical and biotechnology industry. She took responsibility as a general partner at TVM Capital Life Science in 1998, a specialized life science and biotechnology venture capital fund, overseeing and managing the strategic investment decisions, the investment process, deal structuring and exits until the year 2018. She is a Jury member at the Deutscher Zukunftspreis and the Fraunhofer Awards.
She took entrepreneurial responsibility serving in selected boards of private and public portfolio companies in Europe and the USA. She resumed responsibility of strategic development, advising with deep industry insight and leveraging her robust international network. She advised and led company building, financings, IPOs, partnering and licensing programs.
She initiated various lead investments proving a sense for outstanding business opportunities by investing in Actelion Ltd., Idenix Pharmaceuticals, Inc., partially sold to Novartis, and Pharmasset Inc. sold to Gilead Sciences, EUSA Pharma Ltd., sold to Jazz Pharmaceuticals Inc., amongst others.
She started her professional career as Global Business Leader for HIV and CMV, responsible for strategic marketing and business development for Virology at Roche. in Basel. She was involved in the clinical development and managing of commercialization strategies of Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®.
Alexandra Goll holds a degree in pharmacy from the Free University of Berlin and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine. Alexandra is a qualified supervisory board member certified by Deutsche Börse.
She was a columnist for German VC Magazin and was elected one of Europe’s 40 most influential Private Equity and Venture Capital managers by industry voice Private Equity News in 2008.
Phone: +49 172 8320 597
The European Commission provides a platform for online dispute resolution (OS): https://ec.europa.eu/consumers/odr.
Please find our email above.